COMMUNIQUÉS West-GlobeNewswire

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
03/11/2025
CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to [...]
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
03/11/2025
Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target [...]
Climb Bio to Present at Upcoming Investor Conferences
03/11/2025
WELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its [...]
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
03/11/2025
26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif., Nov. 03, 2025 ( [...]
EyePoint Announces Participation at Upcoming Investor Conferences
03/11/2025
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]
Neumora Therapeutics to Participate in Upcoming Conferences in November
03/11/2025
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel [...]
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
03/11/2025
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued [...]
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
03/11/2025
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
03/11/2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet [...]
Jade Biosciences to Participate in Upcoming Conferences
03/11/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune [...]
Multiple Myeloma Research Foundation Joins Forces with Patients and Caregivers for Road to Victories Fundraiser
03/11/2025
MMRF’s four-day Road to Victories ride will raise awareness and funds to accelerate a cure for every patient with multiple myeloma NORWALK, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Multiple Myeloma Research [...]
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
03/11/2025
Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a [...]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
03/11/2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus [...]
IBA intègre l’assurance qualité de l’intelligence artificielle dans ses solutions de dosimétrie grâce à l'acquisition de PhantomX GmbH
03/11/2025
Renforcement du portefeuille de Dosimetry avec l'assurance qualité en imagerie médicale et la validation par IA Louvain-la-Neuve, Belgique, le 3 novembre 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader [...]
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH
03/11/2025
Dosimetry portfolio strengthened with Medical Imaging QA and AI validation Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology [...]
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
03/11/2025
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Halle (Saale) / Munich, Germany, November 3 , 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage [...]
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
03/11/2025
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion Gazyva/Gazyvaro has the potential to be a transformative [...]
BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta
03/11/2025
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced that [...]
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
03/11/2025
LONDON and MILAN, Nov. 03, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful [...]

Pages